Current Perspective On the Use of Calcium Channel Blockers to Treat Hypertensive Patients: the Role of Lercanidipine

Mancia, Giuseppe; Tsioufis, K

doi:10.2217/fca-2019-0008

Cited by 2 publications

(9 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the new European Society of Hypertension/European Society of Cardiology guidelines from 2018 recommend administering a combination of two drugs to control a hypertensive patient, as multitherapy was concluded to be more beneficial [ 59 , 60 ]. Therefore, the initial treatment in most cases should consist of a renin––angiotensin system blocker and a CCB or a diuretic.…”

Section: Lercanidipinementioning

confidence: 99%

“…Therefore, the initial treatment in most cases should consist of a renin––angiotensin system blocker and a CCB or a diuretic. The administration of CCBs, such as lercanidipine, in this combination is especially advantageous in patients with diabetes, coronary artery disease (CAD), cerebrovascular disease (recommendations of grade IA) [ 59 , 60 ].…”

Section: Lercanidipinementioning

confidence: 99%

“…Furthermore, studies have shown that combining lercanidipine with any type of drug allows for a more significant reduction in BP than that exerted by lercanidipine alone [ 49 , 59 , 61 ].…”

Section: Lercanidipinementioning

confidence: 99%

“…Lercanidipine, as a compound of a new generation of CCBs, exhibits pleiotropic actions that are not due to the class effect of these agents but rather them having additional qualities [ 85 , 86 , 87 , 88 ]. They not only influence the reduction in BP, but also exert positive effects on renal parameters, thus limiting their progressive damage [ 12 , 59 ].…”

Section: Nephroprotective Effect Of Lercanidipinementioning

confidence: 99%

See 3 more Smart Citations

New Insights into the Nephroprotective Potential of Lercanidipine

Hajdys,

Fularski,

Leszto

et al. 2023

IJMS

View full text Add to dashboard Cite

Kidneys are responsible for many crucial biological processes in the human body, including maintaining the water–electrolyte balance, pH, and blood pressure (BP), along with the elimination of toxins. Despite this, chronic kidney disease (CKD), which affects more and more people, is a disease that develops insidiously without causing any symptoms at first. The main purpose of this article is to summarize the existing literature on lercanidipine, with a particular focus on its nephroprotective properties. Lercanidipine is a third-generation dihydropyridine (DHP) blocker of calcium channels, and as such it possesses unique qualities such as high lipophilicity and high vascular selectivity. Furthermore, it acts by reversibly inhibiting L-type and T-type calcium channels responsible for exerting positive renal effects. It has been shown to reduce tissue inflammation and tubulointerstitial fibrosis, contributing to a decrease in proteinuria. Moreover, it exhibited antioxidative effects and increased expression of molecules responsible for repairing damaged tissues. It also decreased cell proliferation, preventing thickening of the vascular lumen. This article summarizes studies simultaneously comparing the effect of lercanidipine with other antihypertensive drugs. There is still a lack of studies on the medications used in patients with CKD, and an even greater lack of studies on those used in patients with concomitant hypertension. Therefore, further studies on lercanidipine and its potential in hypertensive patients with coexisting CKD are required.

show abstract

Section: Lercanidipinementioning

confidence: 99%

Section: Lercanidipinementioning

confidence: 99%

“…Furthermore, studies have shown that combining lercanidipine with any type of drug allows for a more significant reduction in BP than that exerted by lercanidipine alone [ 49 , 59 , 61 ].…”

Section: Lercanidipinementioning

confidence: 99%

Section: Nephroprotective Effect Of Lercanidipinementioning

confidence: 99%

See 2 more Smart Citations

New Insights into the Nephroprotective Potential of Lercanidipine

Hajdys,

Fularski,

Leszto

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…People with a high risk of target organ damage and elderly patients may want to consider this medication. In order to optimize the clinical benefit and enhance medication compliance, current hypertension management should be customized for each patient [21]. The BP-lowering and cardiovascular disease and stroke prevention properties of CCBs are remarkable.…”

Section: Role Of Ccb In Hypertension;mentioning

confidence: 99%

Role and Complication of Existing and Newer Calcium Channel Blockers in Hypertension Treatment

Aljehani

Alshahrani

Alhumidi³

et al. 2022

JPRI

View full text Add to dashboard Cite

Hypertension is the major risk factor for cardiovascular disease and early death worldwide. Early and prompt management of hypertension can significantly prevent complications. Owing to the extensive usage of antihypertensive drugs, worldwide mean blood pressure has stayed constant or declined to some extent during the previous four decades although high prevalence in reported in developing countries. CCBs are a class of drugs that are commonly used to lower blood pressure and are structurally and functionally diverse. They are generally well accepted and have less adverse effects. The purpose of this research is to review the available information about role and complication of existing and newer CCBs in hypertension treatment. As soon as CCBs were utilized to treat hypertension, they earned a reputation as potent antihypertensives that significantly and consistently lowered blood pressure in people of all ages and races in mono and combination therapy. CCBs work by reducing peripheral vascular resistance. Newly available CCBs may be therapeutically more effective in treatment of hypertensive individuals with chronic kidney disease than the L-type CCB. Lercanidipine is a third generation CCB that has fewer side effects and is used in people with a high risk of target organ damage and elderly patients. CCBs are associated with certain side effects including peripheral edema, hypotension, headaches, conduction abnormalities among various others. Some studies have also associated use of CCBs with modest risk increase for myocardial infarction and heart failure. Further clinical research is required to elaborately study the efficacy of CCBs in management of hypertension.

show abstract

Current Perspective On the Use of Calcium Channel Blockers to Treat Hypertensive Patients: the Role of Lercanidipine

Cited by 2 publications

References 30 publications

New Insights into the Nephroprotective Potential of Lercanidipine

New Insights into the Nephroprotective Potential of Lercanidipine

Role and Complication of Existing and Newer Calcium Channel Blockers in Hypertension Treatment

Contact Info

Product

Resources

About